Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
|
|
Arbutus Biopharma Corp (ABUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/26/2015 |
8-K/A
| Acquisition/merger/asset purchase announced |
| 01/12/2015 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger and Reorganization, by and among Tekmira Pharmaceuticals Corporation, TKM Acquisition Corporation and OnCore Biopharma, Inc",
"Schedule of signatories to Tekmira Voting Agreement",
"Schedule of signatories to Lock-Up Agreement",
"Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company",
"Presentation Materials",
"Presentation Call Script",
"EDITED TRANSCRIPT TKM.TO - Tekmira Pharmaceuticals Corp and OnCore Biopharma M&A Call EVENT DATE/TIME: JANUARY 12, 2015 / 01:30PM GMT 1 CORPORATE PARTICIPANTS Julie Rezler Tekmira Pharmaceuticals Corporation - Director of IR Mark Murray Tekmira Pharmaceuticals Corporation - President and CEO Vivek Ramaswamy OnCore Biopharma, Inc. - Chairman of the Board Pat Higgins OnCore Biopharma, Inc. - CEO Michael Sofia OnCore Biopharma, Inc. - CTO Tim Block Hepatitis C Foundation - President Bill Symonds OnCore Biopharma, Inc. - Director of the Board Bruce Cousins Tekmira Pharmaceuticals Corporation - CFO CONFERENCE CALL PARTICIPANTS Michael Yee RBC Capital Markets - Analyst Michael Schmidt Leerink Partners - Analyst Stephen Willey Stifel Nicolaus - Analyst David Novak Clarus Securities - Analyst Ben ..." |
|
|
|